Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

1.

The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.

Hopkins AM, O'Doherty CE, Foster DJ, Suppiah V, Upton RN, Spargo LD, Cleland LG, Proudman SM, Wiese MD.

J Clin Pharm Ther. 2014 Oct;39(5):555-60. doi: 10.1111/jcpt.12189. Epub 2014 Jul 8.

PMID:
25040563
2.

Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.

Wiese MD, Suppiah V, O'Doherty C.

Expert Opin Drug Metab Toxicol. 2014 Aug;10(8):1145-59. doi: 10.1517/17425255.2014.925880. Epub 2014 Jun 9. Review.

PMID:
24910969
3.

Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.

Wiese MD, Alotaibi N, O'Doherty C, Sorich MJ, Suppiah V, Cleland LG, Proudman SM.

Pharmacogenomics J. 2014 Aug;14(4):350-5. doi: 10.1038/tpj.2013.45. Epub 2014 Jan 7.

PMID:
24394199
4.

SCN1A variations and response to multiple antiepileptic drugs.

Yip TS, O'Doherty C, Tan NC, Dibbens LM, Suppiah V.

Pharmacogenomics J. 2014 Aug;14(4):385-9. doi: 10.1038/tpj.2013.43. Epub 2013 Dec 17.

PMID:
24342961
5.

Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.

Mahurkar S, Suppiah V, O'Doherty C.

Autoimmun Rev. 2014 Feb;13(2):178-86. doi: 10.1016/j.autrev.2013.10.012. Epub 2013 Nov 2. Review. Erratum in: Autoimmun Rev. 2014 Dec;13(12):1243.

PMID:
24189284
6.

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.

Wiese MD, Rowland A, Polasek TM, Sorich MJ, O'Doherty C.

Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1025-35. doi: 10.1517/17425255.2013.800483. Epub 2013 May 17. Review.

PMID:
23682862
7.

Identification of shared genes and pathways: a comparative study of multiple sclerosis susceptibility, severity and response to interferon beta treatment.

Mahurkar S, Moldovan M, Suppiah V, O'Doherty C.

PLoS One. 2013;8(2):e57655. doi: 10.1371/journal.pone.0057655. Epub 2013 Feb 28.

8.

Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.

O'Doherty C, Schnabl M, Spargo L, Cleland LG, James M, Proudman SM, Wiese MD.

Pharmacogenomics. 2012 Sep;13(12):1427-34. doi: 10.2217/pgs.12.118.

PMID:
22966891
9.

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.

Wiese MD, Schnabl M, O'Doherty C, Spargo LD, Sorich MJ, Cleland LG, Proudman SM.

Arthritis Res Ther. 2012 Jul 12;14(4):R163. doi: 10.1186/ar3911.

10.

The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis.

Main PA, Angley MT, O'Doherty CE, Thomas P, Fenech M.

Nutr Metab (Lond). 2012 Apr 24;9:35. doi: 10.1186/1743-7075-9-35.

11.

Folate and methionine metabolism in autism: a systematic review.

Main PA, Angley MT, Thomas P, O'Doherty CE, Fenech M.

Am J Clin Nutr. 2010 Jun;91(6):1598-620. doi: 10.3945/ajcn.2009.29002. Epub 2010 Apr 21. Review. Erratum in: Am J Clin Nutr. 2010 Oct;92(4):1001.

12.

IL7RA polymorphisms and chronic inflammatory arthropathies.

O'Doherty C, Alloza I, Rooney M, Vandenbroeck K.

Tissue Antigens. 2009 Nov;74(5):429-31. doi: 10.1111/j.1399-0039.2009.01342.x. Epub 2009 Sep 8.

PMID:
19744146
13.

Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.

O'Doherty C, Favorov A, Heggarty S, Graham C, Favorova O, Ochs M, Hawkins S, Hutchinson M, O'Rourke K, Vandenbroeck K.

Pharmacogenomics. 2009 Jul;10(7):1177-86. doi: 10.2217/pgs.09.41.

14.

IL7RA polymorphisms and susceptibility to multiple sclerosis.

O'Doherty C, Kantarci O, Vandenbroeck K.

N Engl J Med. 2008 Feb 14;358(7):753-4. doi: 10.1056/NEJMc0707553. No abstract available.

15.

Clinical screening for obsessive-compulsive and related disorders.

Fineberg NA, Krishnaiah RB, Moberg J, O'Doherty C.

Isr J Psychiatry Relat Sci. 2008;45(3):151-63. Review.

16.

ITGA4 polymorphisms and susceptibility to multiple sclerosis.

O'Doherty C, Roos IM, Antiguedad A, Aransay AM, Hillert J, Vandenbroeck K.

J Neuroimmunol. 2007 Sep;189(1-2):151-7. Epub 2007 Aug 8.

PMID:
17689671
17.

The MHC2TA-168A/G and +1614G/C polymorphisms and risk for multiple sclerosis or chronic inflammatory arthropathies.

O'Doherty C, Hawkins S, Rooney M, Vandenbroeck K.

Tissue Antigens. 2007 Sep;70(3):247-51.

PMID:
17661914
18.

Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes.

O'Doherty C, Villoslada P, Vandenbroeck K.

Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):211-22. Epub 2007 May 30. Review.

PMID:
17540610
19.

CTLA4 gene polymorphisms and multiple sclerosis in Northern Ireland.

Heggarty S, Suppiah V, Silversides J, O'doherty C, Droogan A, McDonnell G, Hawkins S, Graham C, Vandenbroeck K.

J Neuroimmunol. 2007 Jul;187(1-2):187-91. Epub 2007 May 23.

PMID:
17524498
20.

The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis.

Cunningham S, O'Doherty C, Patterson C, McDonnell G, Hawkins S, Marrosu MG, Vandenbroeck K.

J Neuroimmunol. 2007 Feb;183(1-2):208-13. Epub 2006 Dec 18.

PMID:
17175032
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk